CYDY
CytoDyn Inc.
Next earnings Jul 23, 2026
$0.25
▼ -0.48%$0.25▼ -20.39%
over 1Y
L $0.23EODHDH $0.37
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.5%
1W-6.2%
1M-22.9%
3M-5.1%
YTD-8.6%
1Y-20.4%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Conservative balance sheet (liabilities/equity -1.19x); but revenue fell -100.0% YoY.
Revenue (FY2023) $0.00 · FY2023
CytoDyn Inc. shows $0.00 in FY2023 revenue (-100.0% YoY), and -3.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $266K | $0.00 | — | — |
| Gross profit | — | $213K | — | — | — |
| Operating income | -$105M | -$145M | -$40.6M | -$18.1M | $9.66M |
| Net income | -$176M | -$211M | -$79.8M | -$49.8M | $3.75M |
| Diluted EPS | -$0.30 | -$0.31 | -$0.10 | -$0.05 | $0.00 |
| Net margin | — | -79255.6% | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$342M
EV / EBITDA35.4
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield1.2%
FCF yield-2.9%
Quality & risk
ROIC (est.)—
Free cash flow-$8.89M
Total debt$45.3M
Net cash-$33.4M
Altman Z-Score-68.98 distress
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+3.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Reg FD disclosure2026-04-30
- S-1 Securities registration2026-04-22
- 10-Q Quarterly report2026-04-08
- 8-K Material agreement2026-03-24
- 8-K Unregistered share sales2026-03-05
- 10-Q Quarterly report2026-01-09
- 8-K Other event2025-12-01
- 8-K Charter / bylaws change2025-11-21
- S-3 Shelf registration (potential raise)2025-11-04
Recent filings
all on EDGAR ↗EFFECTFiling2026-05-20open ↗424B3Filing2026-05-20open ↗DFiling2026-05-11open ↗8-KPeriod ending 2026-04-302026-04-30open ↗S-1Filing2026-04-22open ↗424B3Filing2026-04-08open ↗10-QPeriod ending 2026-02-282026-04-08open ↗424B3Filing2026-03-25open ↗4Period ending 2026-03-202026-03-24open ↗4Period ending 2026-03-202026-03-24open ↗4Period ending 2026-03-202026-03-24open ↗4Period ending 2026-03-202026-03-24open ↗
Frequently asked
- Is CytoDyn Inc. (CYDY) a buy?
- CYDY currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.19x); but revenue fell -100.0% YoY.
- What is CytoDyn Inc.'s quality score?
- CYDY scores 46.58333333333333/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001175680, latest 10-Q filed 2026-04-08) · EODHD · as of 6/24/2026, 2:28:56 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.